Resource Center

Nucleic ₃ Acid Isolation ® ²

Revvity ² provides a unique and efficient method for isolating nucleic acids based on chemagic™ technology established over 25 years.

Make advancements with precision biologics tools, designed to enhance your therapeutic approaches encompassing monoclonal antibodies, recombinant proteins, vaccines, and targeted next-generation cell and gene therapies.

The recent success of cell and gene therapies has paved the way for the next generation of advanced therapeutics. While challenges remain, cell and gene therapy research is seeing a transformational shift in the way that novel modalities, such as CAR-T, CRISPR, and vectors, are developed and delivered.

Metabolic diseases and disorders disrupt normal metabolism.

New drug modalities and targets are enabling us to live longer and healthier lives— but their development is grounded on a deep understanding of disease onset and progression.

The process of drug development comprises all the activities involved in bringing a new drug to market once a lead compound has been identified.

Identify and characterize drug discovery targets with functional genomic screening services. Offering CRISPR knockout, CRISPR activation, CRISPR inhibition, dual screening and RNAi technologies  

No two cancers are the same —from their genetic makeup to their microenvironment —so the treatment needs to match the uniqueness.

Our optimized, automated solutions are designed to improve the efficiency of your genomic workflows.

Whether you’re trying to understand biology pathways, monitor disease progression, or evaluate drug candidates earlier in drug development, our wide portfolio of preclinical imaging systems are designed to meet your research needs.

From cellular screening and imaging applications to high-throughput screening and genomics-based applications, custom explorer™ G3 integrated workstations

Drug discovery endeavors require a deep understanding of biological systems and their response to potential therapeutics.

Countless diseases, especially cancer, are highly heterogenous in nature which means a one-drug-fitsall approach isn’t practical for treating or fighting these diseases effectively.

With decades of experience in drug discovery driven by strong customer relationships, Revvity has developed an excellent product portfolio of drug discovery tools for complete solutions serving all parts of the discovery workflow.

Test 123